Inspire Medical Systems (NYSE:INSP) Director Marilyn C. Nelson sold 15,000 shares of the business’s stock in a transaction on Friday, December 6th. The shares were sold at an average price of $75.05, for a total transaction of $1,125,750.00. Following the completion of the transaction, the director now directly owns 2,234 shares of the company’s stock, valued at approximately $167,661.70. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Shares of INSP stock opened at $72.87 on Wednesday. The company has a debt-to-equity ratio of 0.17, a quick ratio of 13.05 and a current ratio of 13.42. The company has a market capitalization of $1.76 billion, a P/E ratio of -48.58 and a beta of 1.27. The company’s 50 day moving average price is $65.06 and its two-hundred day moving average price is $62.81. Inspire Medical Systems has a 52 week low of $35.43 and a 52 week high of $75.91.

Inspire Medical Systems (NYSE:INSP) last announced its quarterly earnings results on Tuesday, November 5th. The company reported ($0.34) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.43) by $0.09. The firm had revenue of $20.86 million for the quarter, compared to analyst estimates of $19.15 million. Inspire Medical Systems had a negative net margin of 40.36% and a negative return on equity of 18.67%. The business’s revenue was up 59.8% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($0.22) earnings per share. Analysts forecast that Inspire Medical Systems will post -1.46 earnings per share for the current year.

Several analysts recently commented on INSP shares. ValuEngine downgraded Inspire Medical Systems from a “hold” rating to a “sell” rating in a research note on Thursday, October 31st. Zacks Investment Research raised Inspire Medical Systems from a “hold” rating to a “strong-buy” rating and set a $69.00 target price for the company in a research note on Saturday, November 9th. Dougherty & Co set a $78.00 target price on Inspire Medical Systems and gave the company a “buy” rating in a research note on Friday, September 27th. Finally, Berenberg Bank upgraded Inspire Medical Systems from a “sell” rating to a “hold” rating and increased their price target for the stock from $46.00 to $51.00 in a report on Wednesday, November 6th. One analyst has rated the stock with a sell rating, two have issued a hold rating, one has given a buy rating and one has issued a strong buy rating to the company. The stock currently has an average rating of “Hold” and a consensus price target of $68.25.

Large investors have recently modified their holdings of the stock. Morgan Stanley boosted its stake in shares of Inspire Medical Systems by 3.6% in the 2nd quarter. Morgan Stanley now owns 1,441,080 shares of the company’s stock valued at $87,401,000 after purchasing an additional 50,166 shares during the last quarter. BlackRock Inc. boosted its holdings in shares of Inspire Medical Systems by 43.5% in the 2nd quarter. BlackRock Inc. now owns 1,406,301 shares of the company’s stock worth $85,293,000 after purchasing an additional 426,425 shares in the last quarter. William Blair Investment Management LLC boosted its holdings in shares of Inspire Medical Systems by 5.9% in the 2nd quarter. William Blair Investment Management LLC now owns 1,160,880 shares of the company’s stock worth $70,407,000 after purchasing an additional 64,785 shares in the last quarter. Invesco Ltd. increased its position in shares of Inspire Medical Systems by 279.8% during the 2nd quarter. Invesco Ltd. now owns 965,710 shares of the company’s stock valued at $58,570,000 after purchasing an additional 711,435 shares during the last quarter. Finally, Vanguard Group Inc. increased its position in shares of Inspire Medical Systems by 12.8% during the 2nd quarter. Vanguard Group Inc. now owns 795,694 shares of the company’s stock valued at $48,258,000 after purchasing an additional 90,413 shares during the last quarter. Institutional investors and hedge funds own 89.69% of the company’s stock.

Inspire Medical Systems Company Profile

Inspire Medical Systems, Inc, a medical technology company, focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA). It offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe obstructive sleep apnea.

Featured Story: What is the CAC 40 Index

Insider Buying and Selling by Quarter for Inspire Medical Systems (NYSE:INSP)

Receive News & Ratings for Inspire Medical Systems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inspire Medical Systems and related companies with MarketBeat.com's FREE daily email newsletter.